Shang Xiyu, Cao Yuqing, Guo Yang, Zhang Lei, Li Jiajia, Zhang Huifang, Fan Yipin, Huang Yuxuan, Li Jiantao, Wang Yanping, Xiong Yibai, Cai Qiujie, Zhang Huamin, Ma Yan
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
Institute of Traditional Chinese Medicine Information, Chinese Academy of Traditional Chinese Medicine, Beijing, 100700, People's Republic of China.
Infect Dis Poverty. 2024 Dec 19;13(1):97. doi: 10.1186/s40249-024-01263-8.
Traditional Chinese medicine (TCM) has developed a rich theoretical system and practical experience in fighting to infectious diseases over the past thousands of years, and has played an important role in controlling the spread owing to its unique advantages. In particular, its significant contribution to the prevention and control of Corona Virus Disease 2019 (COVID-19) is widely recognized. COVID-19 infection is mainly non-severe with a favorable overall outcome, but patients with comorbidities tend to have a poor prognosis. However, a comprehensive review of TCM for preventing and treating COVID-19 with comorbidities across various systems is still lacking. Hence, this scoping review aims to conduct a comprehensive investigation on treatment outcome of TCM for treating COVID-19 with comorbidities across various systems.
The scoping review was conducted by searching English databases including PubMed and Web of Science, and Chinese databases including China National Knowledge Infrastructure and Wanfang between January 2020 and January 2024. We followed the inclusion and exclusion criteria to identify relevant literature. Information for inclusion in the literature were subsequently extracted and consolidated.
We enrolled 13 literature that met the inclusion criteria in the review finally. Our analysis revealed that research on COVID-19 with comorbidities was mostly focused on circulatory diseases, including hypertension, heart failure, and cerebrovascular diseases, most common comorbidities were hypertension. Followed by endocrine and metabolic diseases such as diabetes, respiratory diseases including pulmonary tuberculosis and chronic obstructive pulmonary disease have been also addressed. However, there were few studies on co-infectious urogenital system disease, and no studies on the rheumatic, immune, hematological, nervous, reproductive, and skin systems diseases. Based on existing studies, TCM has significantly improved the clinical symptoms of COVID-19 with comorbidities such as fever, fatigue, dry cough, anorexia and asthma, the absorption of lung lesions, shortened the duration of viral shedding and the course of disease.
TCM has great application prospects in treating COVID-19 with comorbidities. These findings could provide important evidence for clinicians to treat COVID-19 with comorbidities. Multi-center studies are required to confirm our results in the future.
在过去几千年里，中医在抗击传染病方面形成了丰富的理论体系和实践经验，凭借其独特优势在控制疫情传播中发挥了重要作用。尤其是其对2019冠状病毒病（COVID-19）防控的重大贡献得到广泛认可。COVID-19感染大多为轻症，总体预后良好，但合并症患者预后往往较差。然而，目前仍缺乏对中医在治疗各系统合并COVID-19方面的全面综述。因此，本范围综述旨在全面调查中医治疗各系统合并COVID-19的治疗效果。
本范围综述通过检索2020年1月至2024年1月期间的英文数据库（包括PubMed和Web of Science）以及中文数据库（包括中国知网和万方）进行。我们遵循纳入和排除标准来确定相关文献。随后提取并整合纳入文献的信息。
我们最终纳入了13篇符合纳入标准的文献。分析显示，合并COVID-19的研究主要集中在循环系统疾病，包括高血压、心力衰竭和脑血管疾病，最常见的合并症是高血压。其次是内分泌和代谢疾病如糖尿病，也涉及呼吸系统疾病如肺结核和慢性阻塞性肺疾病。然而，关于合并泌尿生殖系统感染性疾病的研究较少，关于风湿、免疫、血液、神经、生殖和皮肤系统疾病则没有研究。基于现有研究，中医显著改善了合并COVID-19患者的发热、乏力、干咳、厌食和气喘等临床症状，促进了肺部病变的吸收，缩短了病毒脱落持续时间和病程。
中医治疗合并COVID-19具有广阔的应用前景。这些发现可为临床医生治疗合并COVID-19提供重要依据。未来需要多中心研究来证实我们的结果。
